Top Pharmaceutical Companies in Los Angeles, CA (63)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Profitability: Adjusted EBITDA remained robust in 2025 (about $270M, ~34% margin) and 2026 guidance was lifted to $240–$250M, indicating healthy margins despite softer top-line trends. Strong quarterly EBITDA and cash generation in 1H 2026 underscore financial durability through the transition.
Diversified Revenue Streams: Pharma Direct and subscriptions are scaling quickly (Pharma Direct +41% in 2025 and +76–82% YoY in 1H 2026; subscriptions +16% in Q1 and +39% in Q2 2026), broadening the mix beyond the legacy coupon business. Management continues to position these segments as key growth drivers that can offset core declines over time.
Product Line Growth: New offerings such as condition‑specific programs (notably weight‑loss/GLP‑1), the GoodRx Companion membership, and initiatives like Employer Direct expand the product footprint. Deeper manufacturer relationships and program integrations (including presence on the federal TrumpRx.gov platform) further extend the solution set.
O POSITIV is about feeling your best. We make vitamins for real people, in real life, with the belief that small acts of self-care produce positive outcomes. Because personal health should be effortless and intentional
Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with...
We are alchemists at heart, harnessing science to create powerful wellness solutions. The combination of alchemy and “me” offers the right mixture of science, expertise, and support that empowers our customers with confidence. Through one-of-a-kind expert-designed formulas and positive guidance, Alchemee provides solutions that are as effective as they are transformative. At Alchemee, we are committed to empowering the world one person at a...
Caprion Biosciences was a leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry, specializing in advanced immunology and proteomics services. It has since rebranded to CellCarta, a global contract research organization.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. We are powered...
Novo Nordisk's Top Stability & Growth Strengths
Strong Market Position & Advantage: Novo Nordisk is characterized as a global leader in GLP‑1–based diabetes and obesity care, anchored by clinically differentiated products like Wegovy and a broad GLP‑1 portfolio. While shares fluctuate by geography, disclosures and independent analyses continue to frame the company as a category leader.
Innovation-Driven Growth: Cardiovascular outcomes data supporting Wegovy’s label expansion and the first approved oral GLP‑1 for chronic weight management, together with late‑stage assets (e.g., amycretin/zenagamtide, CagriSema), strengthen adoption arguments and extend the franchise.
Market Expansion: U.S. launch momentum for the Wegovy pill, EU approval, and planned international rollouts in 2026 are broadening access and the addressable market. Significant capacity additions, including acquired fill‑finish sites and new investments, are intended to support higher volumes across regions.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our pipeline includes tipifarnib, a farnesyl...
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is a leading nonprofit research organization focused on biomedical innovation, translating discovery into health impact through research, education, and community outreach.
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 41,000 global...
Seragon is a research-based biopharmaceutical company, committed to innovating cutting-edge discoveries in biotechnology and medicine.
ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients. ACELYRIN is embedding a corporate culture of Courageous Caring™—placing patients first and embracing the concept that all of us are better than any...
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
Thrivelab is a telehealth-based provider of evidence-based hormone and testosterone balancing programs as well as natural bioidentical products to alleviate age-related symptoms and restore youthful vitality.
Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of cell and exosome-based therapeutics. Its lead product candidate, Deramiocel, is an allogeneic cell therapy currently in late-stage clinical development for the treatment of Duchenne muscular dystrophy (DMD). The company also leverages its proprietary StealthX™ exosome platform for the targeted delivery of therapeutic agents to treat...
IPS-Integrated Project Services, LLC, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve...
A global leader in developing and producing responsible packaging for food, beverage, pharma, medical, home- and personal-care, and other products. Amcor works with leading companies around the world to protect their products and the people who rely on them, differentiate brands, and improve supply chains through a range of flexible and rigid packaging, specialty cartons, closures, and services. The company...
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best. The neuroscience market is on a growth trajectory. We see...
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have...
Mixlab is the first modern, tech-enabled pet pharmacy that focuses on creating custom medications and delightful experiences for pets, their parents and veterinarians. By putting service at the heart of everything we do, our talented team is able to provide the best personalized care for our patients, as well as those who care for them.
Mixlab's Top Stability & Growth Strengths
Market Expansion: The company expanded from a few labs to a multi‑site footprint across NY, CA, FL, TX, and WI with shipping to all 50 states and same‑/next‑day options in select markets. Acquisitions in 2024–2025 (e.g., NexGen, The Pet Apothecary, SBH Medical’s veterinary business) broadened geographic coverage and capacity.
Investor Backing & Capital Strength: Recent capital raises, including a $10M round in 2023, funded nationwide scaling and platform development. Investor support is tied to new facilities and acquisitions that extend operational reach.
Innovation-Driven Growth: Technology integrations (e.g., Vetcove, Vetsource, Instinct EMR), a new client portal, and launch of an AI health partner (Maisy) underpin a tech‑first growth strategy. The model emphasizes a modern, veterinary‑friendly digital workflow and fast fulfillment.
